#Avoiding side effect of metformin trial#
#Avoiding side effect of metformin simulator#

#Avoiding side effect of metformin simulator#

Metformin’s ability to stop the virus was predicted by a simulator developed by U of M Medical School and College of Science and Engineering Biomedical Engineering faculty. Further research could show whether it is also effective in those with previous infection or in adults with lower body mass index.”

#Avoiding side effect of metformin trial#

“While half of our trial had been vaccinated, none had been previously infected with the COVID-19 virus. Bramante, who is also an internist and pediatrician with M Health Fairview. “This long-term outcome from a randomized trial is high-quality evidence that metformin prevents harm from the SARS-CoV-2 virus,” said Dr. Over 1,100 of the participants reported on their symptoms for up to 10 months after their initial COVID-19 diagnosis. Participants were between 30 and 85 years old who qualified as overweight or obese. The study included more than 1,200 participants who were randomly chosen to receive either metformin or placebo, and an additional subset received ivermectin, fluvoxamine or their placebos. The UNC School of Medicine was not a site for the clinical trial. Caviness Distinguished Professor of Medicine and senior associate dean for clinical research at the UNC School of Medicine.īuse, who co-led the conception, design and oversight of the study, is the director of the NC Translational and Clinical Sciences ( NC TraCS) Institute. “Not only did we demonstrate that metformin, an inexpensive and safe treatment, may prevent the development of long COVID in many people, but we validated that long COVID is a real disease in that a 14-day treatment can reduce the risk of long COVID symptoms and a doctor’s diagnosis over many months,” said John Buse, MD, PhD, the Verne S.

Ivermectin and fluvoxamine did not prevent long COVID.

The effect was consistent across different demographic populations of volunteers who participated and across multiple viral variants, including the Omicron variant.

For participants who started metformin less than four days after their COVID symptoms started, metformin decreased the risk of long COVID by 63%.

Those who received metformin were more than 40% less likely to develop long COVID than those who received an identical looking placebo.

This was a large, placebo-controlled randomized clinical trial which enrolled volunteers across the United States. “Metformin is an inexpensive, safe and widely available drug, and its use as a preventive measure could have significant public health implications.” “The results of this study are important because long COVID can have a significant impact on people’s lives,” said Carolyn Bramante, MD, principal investigator and an assistant professor at the University of Minnesota Medical School. Long COVID is a chronic illness that can affect up to 10% of people who have had COVID-19.

The study, called COVID-OUT, investigated if early outpatient COVID-19 treatment with metformin, ivermectin or fluvoxamine could prevent long COVID. In a new study published in The Lancet Infectious Diseases, University of Minnesota researchers and colleagues found that metformin, a drug commonly used to treat diabetes, prevents the development of long COVID. The clinical trial was led by researchers at the University of Minnesota. John Buse, MD, PhD, co-authored a study showing that the common diabetes drug metformin substantially decreased the risk of developing long COVID after infection from SARS-CoV-2.